The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
Abstract
Summary: In anecdotal reports, some patients with immune thrombocytopenia (ITP) maintained platelet counts after discontinuing romiplostim. Here, we examined rates of platelet response (≥50 × 10 9/l), remission, splenectomy and adverse events in patients with primary ITP duration ≤6 months who were treated with romiplostim for ≤12 months. The starting dose of romiplostim was 1 μg/kg; concomitant and rescue treatments were permitted to maintain platelet counts. Patients with platelet counts ≥50 × 10 9/l at the end of 12 months entered a dose taper in which the romiplostim dose was decreased as long as platelet counts were maintained. Remission (platelet count ≥50 × 10 9/l for 24 consecutive weeks with no ITP treatments) was evaluated in patients once romiplostim was discontinued. Over the 12 months, a high response rate (>90%) was observed. Platelet response occurred quickly (median, ~2 weeks) and was observed for a cumulative median of 11 months. Remission was observed in 24 patients (32%); there were no significantly predictors of remission. Most (20/24) patients had remission start before the forced taper. No new safety signals were identified. Thus, in patients with early‐stage ITP, romiplostim was well tolerated and induced rapid responses, with remission occurring in approximately one‐third of patients (NCT 01143038, Amgen 20080435).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Libert, C., & Dejager, L. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.041 · Cited by 69
Cited by
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Neunert, C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., Cuker, A., Despotovic, J. M., George, J. N., Grace, R. F., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000966 · Cited by 1,406
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Zufferey, A., Kapur, R., & Semple, J. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6020016 · Cited by 566
Cooper, N., & Ghanima, W. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1810479 · Cited by 503
Clinical updates in adult immune thrombocytopenia
Lambert, M. P., & Gernsheimer, T. B. (2017) · Blood · doi:10.1182/blood-2017-03-754119 · Cited by 445
Thrombopoietin receptor agonists: ten years later
Ghanima, W., Cooper, N., Rodeghiero, F., Godeau, B., & Bussel, J. B. (2019) · Haematologica · doi:10.3324/haematol.2018.212845 · Cited by 416
Self-citation
Metadata
- Authors
- Newland, A., Godeau, B., Priego, V., Viallard, J., López Fernández, M. F., Orejudos, A., & Eisen, M.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2015-11-05
- Volume
- 172
- Issue
- 2
- Pages
- 262-273
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1940859004
- Cited by
- 176
- References
- 1
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. https://app.cochat.ai/papers/10.1111/bjh.13827
- The paper
- Newland, A., Godeau, B., Priego, V., Viallard, J., López Fernández, M. F., Orejudos, A., & Eisen, M. (2016). Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. British Journal of Haematology. https://doi.org/10.1111/bjh.13827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.